Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
| ▸ | PRKACG | P22612 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10295486 | 0.94 | MET (0.60) | METCYP3A4KCNH2PRKACG | |
| SCHEMBL10295487 | 0.88 | MET (0.65) | METCYP3A4KCNH2PRKACG | |
| SCHEMBL9910257 | 0.87 | MET (0.88) | METCYP3A4PRKACG | |
| SCHEMBL9910196 | 0.86 | MET (0.89) | METCYP3A4KCNH2 | |
| SCHEMBL9910159 | 0.85 | MET (0.75) | METCYP3A4KCNH2PRKACG | |
| SCHEMBL9910256 | 0.85 | MET (0.86) | METCYP3A4KCNH2 | |
| SCHEMBL13857039 | 0.82 | MET (0.59) | METCYP3A4KCNH2PRKACG | |
| SCHEMBL9910253 | 0.81 | MET (0.80) | METCYP3A4PRKACG | |
| SCHEMBL9910247 | 0.81 | MET (1.00) | METCYP3A4PRKACG | |
| SCHEMBL10295489 | 0.80 | MET (0.58) | METCYP3A4KCNH2PRKACG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | MET 3/4885CYP3A4 118/4885KCNH2 4715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.